WEST PHARMACEUTICAL SERVICES, INC. (WST) Current Ratio
- Current ratio · latest quarter: Value 2.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.82× | Current assets / current liabilities. $1.81B ÷ $640.50M ≈ 2.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.81B USD | Assets, Current |
| Current obligations | 640.50M USD | Liabilities, Current |
| Cash and equivalents | 435.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 712.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 447.40M USD | Inventory, Net |
| Payables | 252.70M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.81B | $640.50M | $435.80M | (m) | $712.00M | $447.40M | $252.70M | $0.00 | 2.82× |
| 2026-03-31 | $1.83B | $674.00M | $521.40M | (m) | $685.60M | $452.60M | $252.30M | $0.00 | 2.71× |
| 2025-12-31 | $1.98B | $654.90M | $791.30M | (m) | $574.40M | $443.90M | $253.70M | $0.00 | 3.02× |
| 2025-09-30 | $1.82B | $635.40M | $628.50M | (m) | $625.00M | $438.00M | $255.80M | $0.00 | 2.87× |
| 2025-06-30 | $1.68B | $604.60M | $509.70M | (m) | $582.40M | $421.10M | $239.00M | $0.00 | 2.78× |
| 2025-03-31 | $1.46B | $526.70M | $404.20M | (m) | $543.60M | $388.70M | $228.40M | $0.00 | 2.77× |
| 2024-12-31 | $1.54B | $550.40M | $484.60M | (m) | $552.50M | $377.00M | $239.30M | $0.00 | 2.79× |
| 2024-09-30 | $1.55B | $516.50M | $490.90M | (m) | $524.30M | $401.20M | $224.30M | $0.00 | 3.00× |
| 2024-06-30 | $1.48B | $633.70M | $446.20M | (m) | $479.40M | $419.20M | $211.70M | $132.90M | 2.34× |
| 2024-03-31 | $1.69B | $648.40M | $601.80M | (m) | $524.00M | $429.90M | $240.10M | $133.40M | 2.61× |
| 2023-12-31 | $1.94B | $671.80M | $853.90M | (m) | $512.00M | $434.70M | $242.40M | $134.00M | 2.88× |
| 2023-09-30 | $1.97B | $533.50M | $898.60M | (m) | $519.10M | $431.80M | $219.80M | $55.20M | 3.70× |
| 2023-06-30 | $1.87B | $511.60M | $796.30M | (m) | $534.40M | $449.40M | $218.00M | $2.20M | 3.66× |
| 2023-03-31 | $1.94B | $534.90M | $886.30M | (m) | $513.40M | $447.00M | $233.80M | $2.20M | 3.62× |
| 2022-12-31 | $1.92B | $519.00M | $894.30M | (m) | $507.40M | $414.80M | $215.40M | $2.20M | 3.70× |
| 2022-09-30 | $1.73B | $456.70M | $729.00M | (m) | $485.30M | $413.10M | $188.90M | $2.20M | 3.80× |
| 2022-06-30 | $1.77B | $565.10M | $718.50M | (m) | $528.40M | $411.60M | $220.00M | $44.20M | 3.13× |
| 2022-03-31 | $1.69B | $584.80M | $667.70M | (m) | $498.70M | $416.50M | $248.20M | $44.20M | 2.89× |
| 2021-12-31 | $1.74B | $594.10M | $762.60M | (m) | $489.00M | $378.40M | $232.20M | $44.20M | 2.93× |
| 2021-09-30 | $1.60B | $558.60M | $688.00M | (m) | $476.40M | $353.80M | $207.70M | $44.20M | 2.86× |
| 2021-06-30 | $1.48B | $472.60M | $576.20M | (m) | $480.50M | $345.20M | $205.10M | $2.30M | 3.13× |
| 2021-03-31 | $1.33B | $482.80M | $483.70M | (m) | $465.70M | $310.20M | $204.30M | $2.30M | 2.75× |
| 2020-12-31 | $1.37B | $503.40M | $615.50M | (m) | $385.30M | $321.30M | $213.10M | $2.30M | 2.73× |
| 2020-09-30 | $1.24B | $447.70M | $519.40M | (m) | $373.00M | $294.90M | $180.30M | $2.30M | 2.77× |
| 2020-06-30 | $1.11B | $375.20M | $445.90M | (m) | $340.60M | $274.80M | $162.30M | $2.30M | 2.96× |
| 2020-03-31 | $977.50M | $344.40M | $335.30M | (m) | $333.00M | $251.00M | $157.90M | (m) | 2.84× |
| 2019-12-31 | $1.06B | $341.60M | $439.10M | (m) | $319.30M | $235.70M | $156.80M | $2.30M | 3.10× |
| 2019-09-30 | $1.00B | $335.00M | $396.00M | (m) | $316.10M | $230.40M | $145.30M | (m) | 3.00× |
| 2019-06-30 | $944.30M | $313.20M | $326.70M | (m) | $330.80M | $232.30M | $152.10M | (m) | 3.02× |
| 2019-03-31 | $867.60M | $301.10M | $265.50M | (m) | $318.20M | $226.10M | $137.70M | (m) | 2.88× |
| 2018-12-31 | $894.40M | $283.70M | $337.40M | (m) | $288.20M | $214.50M | $130.40M | (m) | 3.15× |
| 2018-09-30 | $850.10M | $288.80M | $297.30M | (m) | $302.90M | $206.80M | $125.20M | (m) | 2.94× |
| 2018-06-30 | $766.90M | $287.60M | $225.50M | (m) | $296.70M | $208.20M | $126.20M | (m) | 2.67× |
| 2018-03-31 | $743.50M | $263.40M | $199.80M | (m) | $290.40M | $215.70M | $127.60M | (m) | 2.82× |
| 2017-12-31 | $743.50M | $279.50M | $235.90M | (m) | $253.20M | $215.20M | $138.10M | (m) | 2.66× |
| 2017-09-30 | $776.90M | $300.00M | $269.30M | (m) | $251.80M | $215.80M | $121.90M | (m) | 2.59× |
| 2017-06-30 | $717.80M | $289.00M | $226.60M | (m) | $242.40M | $211.30M | $130.90M | (m) | 2.48× |
| 2017-03-31 | $652.60M | $256.50M | $169.40M | (m) | $224.80M | $212.30M | $106.10M | (m) | 2.54× |
| 2016-12-31 | $641.90M | $241.00M | $203.00M | (m) | $200.50M | $199.30M | $122.00M | (m) | 2.66× |
| 2016-09-30 | $658.10M | $236.80M | $205.90M | (m) | $209.50M | $201.10M | $99.00M | (m) | 2.78× |
| 2016-06-30 | $659.20M | $239.40M | $202.70M | (m) | $219.00M | $197.70M | $107.30M | (m) | 2.75× |
| 2016-03-31 | $630.70M | $241.10M | $178.10M | (m) | $209.60M | $194.10M | $97.50M | (m) | 2.62× |
| 2015-12-31 | $673.70M | $314.30M | $274.60M | (m) | $181.40M | $181.10M | $119.80M | (m) | 2.14× |
| 2015-09-30 | $680.90M | $299.90M | $256.80M | (m) | $194.60M | $187.70M | $93.60M | (m) | 2.27× |
| 2015-06-30 | $679.90M | $313.70M | $252.00M | (m) | $198.80M | $187.20M | $91.40M | (m) | 2.17× |
| 2015-03-31 | $625.10M | $296.60M | $207.10M | (m) | $189.50M | $183.40M | $88.50M | (m) | 2.11× |
| 2014-12-31 | $659.10M | $252.50M | $255.30M | (m) | $179.00M | $181.50M | $103.10M | (m) | 2.61× |
| 2014-09-30 | $679.50M | $242.50M | $246.80M | (m) | $195.90M | $185.70M | $91.40M | (m) | 2.80× |
| 2014-06-30 | $685.40M | $221.20M | $226.70M | (m) | $209.60M | $187.90M | $94.50M | (m) | 3.10× |
| 2014-03-31 | $686.60M | $227.60M | $230.00M | (m) | $208.70M | $187.50M | $98.40M | (m) | 3.02× |
| 2013-12-31 | $650.70M | $236.90M | $230.00M | (m) | $185.70M | $176.90M | $108.00M | (m) | 2.75× |
| 2013-09-30 | $643.50M | $246.80M | $221.70M | (m) | $198.20M | $176.70M | $86.30M | (m) | 2.61× |
| 2013-06-30 | $613.30M | $218.70M | $190.60M | (m) | $195.30M | $176.50M | $88.40M | (m) | 2.80× |
| 2013-03-31 | $589.70M | $208.10M | $175.00M | (m) | $189.00M | $173.50M | $91.60M | (m) | 2.83× |
| 2012-12-31 | $557.30M | $261.80M | $161.90M | (m) | $175.00M | $162.20M | $102.90M | (m) | 2.13× |
| 2012-09-30 | $557.30M | $275.60M | $143.20M | (m) | $182.90M | $165.90M | $81.30M | (m) | 2.02× |
| 2012-06-30 | $517.00M | $320.20M | $107.00M | (m) | $185.00M | $159.20M | $85.60M | (m) | 1.61× |
| 2012-03-31 | $502.80M | $302.40M | $100.20M | (m) | $176.00M | $158.20M | $82.70M | (m) | 1.66× |
| 2011-12-31 | $472.00M | $243.20M | $91.80M | (m) | $147.20M | $151.80M | $89.80M | (m) | 1.94× |
| 2011-09-30 | $503.50M | $229.30M | $119.20M | (m) | $153.10M | $155.50M | $71.70M | (m) | 2.20× |
| 2011-06-30 | $510.40M | $192.70M | $110.40M | (m) | $165.70M | $161.20M | $73.40M | (m) | 2.65× |
| 2011-03-31 | $481.10M | $182.80M | $94.60M | (m) | $161.20M | $157.10M | $66.20M | (m) | 2.63× |
| 2010-12-31 | $436.60M | $169.70M | $110.20M | (m) | $126.40M | $147.00M | $63.20M | (m) | 2.57× |
| 2010-09-30 | $441.20M | $158.20M | $97.10M | (m) | $142.80M | $148.40M | $56.30M | (m) | 2.79× |
| 2010-06-30 | $403.90M | $158.60M | $67.50M | (m) | $145.70M | $143.30M | $61.40M | (m) | 2.55× |
| 2009-12-31 | $397.20M | $171.10M | $83.10M | (m) | $138.70M | $129.20M | $68.40M | (m) | 2.32× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |